ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 596

Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis

Kensuke Kume1, Kanzo Amano1, Susumu Yamada2, Toshikatsu Kanazawa2 and Kazuhiko Hatta3, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2rheumatology, hiroshima clinic, hiroshima, Japan, 3Rheumatology, Hatta Clinic, Kure, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), steroids and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, we experienced that rapid radiographic progression (RRP) existed despite initial tofacitinib and methotrexate combination therapy in early RA (unpublished data). In RRP, initial tofacitinib and methotrexate might be inadequate. To compare remission and radiographic non-progression in RRP patients treated with tofacitinib or with tofaficitinib plus intra-articular steroid injection.

Methods: We designed a single-blind(X ray reader and assessment physician), randomized controlled trial. We screened 48 RRP (CRP> 10 mg/L, RF +, and ACPA+) early (disease duration<6 months) RA patients for inclusion. 39 were randomly allocated tofacitinib group (T group) or tofacitinib plus intra-articular steroid injection group (T plus I group). All patients were taking methotrexate (from 10 to 22mg a week). For T plus I group, palpate examinations of both MP and PIP joints, wrists, elbows, shoulders, and knees were performed every 4 weeks. If swollen joints were existed, intra-articular steroid injections were intensified in each swollen joints. Co–primary endpoints were proportion of patients showing clinical remission (SDAI <3.3) and radiographic non-progression (Δ modified total Sharp score ≤0.5) at 52 weeks. Analysis was by intention-to-treat with last observation carried forward to missing data.

Results: The characteristics of each group at baseline were not significantly different. Clinical remission at 52weeks was achieved by more patients in the T plus I group (29.2%) than in the T group (21.3%) (p<0.05). Radiographic non-progression at 52 weeks was achieved by more patients in the T plus I group (33.4%) than in the C group (23.7%) (p<0.05).

Conclusion: Results of this reveal that combination of intra-articular steroid injection and tofacitinib can achieve a high clinical and radiological remission rate in early RRP RA.

References:

1) Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Durnez A, et al. Ann Rheum Dis. 2011 Apr;70(4):634-7. Epub 2010 Dec 21.

2) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Visser K, et al. Ann Rheum Dis. 2010 Jul;69(7):1333-7. Epub 2010 May 24.


Disclosure: K. Kume, None; K. Amano, None; S. Yamada, None; T. Kanazawa, None; K. Hatta, None.

To cite this abstract in AMA style:

Kume K, Amano K, Yamada S, Kanazawa T, Hatta K. Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/combination-of-intra-articular-steroid-injection-and-tofacitinib-more-effective-than-tofacitinib-in-rapid-radiographic-progression-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combination-of-intra-articular-steroid-injection-and-tofacitinib-more-effective-than-tofacitinib-in-rapid-radiographic-progression-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology